| APOE gene polymorphisms and response to statin therapy. | |
| | |
MedLine Citation:
|
PMID: 19529002 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Published studies investigating the role of APOE gene on lipid response (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides) to statin treatment have reported inconsistent results. A meta-analysis was conducted to estimate the lipid response to statin treatment among APOE genetic variants (e2 carriers, e3e3 homozygotes and e4 carriers). Twenty-four studies were included in the meta-analyses. The pooled mean reduction (Delta mu) in TC from baseline was significant for all variants (e2 carriers: Delta mu=-27.7% (-32.5 to -22.8%), e3e3: Delta mu=-25.3% (-28.0 to -22.6%) and e4 carriers: Delta mu=-25.1% (-29.3 to -21.0%)). Significant changes in LDL-C, HDL-C and triglyceride levels were also noted for all genotypes, although these changes did not differ significantly among genotypic groups. There was significant heterogeneity among the studies. Given these non-significant effects of APOE genotypes on lipid responses, there is little reason to consider the use of APOE genetic testing for guiding treatment with statins. |
| | |
Authors:
|
E Zintzaras; G D Kitsios; F Triposkiadis; J Lau; G Raman |
Publication Detail:
|
Type: Journal Article; Meta-Analysis Date: 2009-06-16 |
Journal Detail:
|
Title: The pharmacogenomics journal Volume: 9 ISSN: 1473-1150 ISO Abbreviation: Pharmacogenomics J. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-07-23 Completed Date: 2009-11-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101083949 Medline TA: Pharmacogenomics J Country: United States |
Other Details:
|
Languages: eng Pagination: 248-57 Citation Subset: IM |
Affiliation:
|
Department of Biomathematics, University of Thessaly School of Medicine, Larissa, Greece. zintza@med.uth.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Apolipoproteins E
/
genetics* Cholesterol, HDL / metabolism* Cholesterol, LDL / metabolism* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Hypercholesterolemia / drug therapy*, genetics* Polymorphism, Single Nucleotide Triglycerides / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoproteins E; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Triglycerides |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodula...
Next Document: Italian public school: a survey to estimate teachers' knowledge and perception on prevention and man...